Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 7:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 2,571 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Hematopoietic stem cell transplant Clear all
Active, not recruiting Not applicable Interventional

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies

NCT01652092
View directory record Official record
Conditions
SCID, Omenn's Syndrome, Reticular Dysgenesis, Wiskott-Aldrich Syndrome, Bare Lymphocyte Syndrome, Common Variable Immunodeficiency, Chronic Granulomatous Disease, CD40 Ligand Deficiency, Hyper IgM Syndrome, X-linked Lymphoproliferative Disease, Hemophagocytic Lymphohistiocytosis, Griscelli Syndrome, Chediak-Higashi Syndrome, Langerhan's Cell Histiocytosis
Interventions
Alemtuzumab 0.3 mg, Cyclophosphamide, Busulfan, Stem Cell Transplantation, Fludarabine phosphate 40 mg, Melphalan, Alemtuzumab 0.2 mg, Fludarabine phosphate 30 mg, MESNA
Drug · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 50 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 15, 2026, 7:53 PM EDT
Completed Phase 2 Interventional Results available

Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation

NCT02210065
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
Cytomegalovirus (CMV)-Specific Cytotoxic T Cells (CTLs)
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Oct 15, 2026, 7:53 PM EDT
Active, not recruiting Not applicable Interventional

Psychosocial Mobile App for Chronic Graft-Versus-Host Disease

NCT05690971
View directory record Official record
Conditions
Chronic Graft-Versus-Host Disease, Allogeneic Stem Cell Transplant
Interventions
App, Usual Care
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 15, 2026, 7:53 PM EDT
Completed No phase listed Observational

Analysis of T Cell and Natural Killer (NK) Cell in Relation to Viral Infections in Pediatric Stem Cell Transplant Patients and Donors

NCT02301065
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Oct 15, 2026, 7:53 PM EDT
Completed Phase 2 Interventional Results available

Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients

NCT01402284
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Carfilzomib, Lenalidomide, Dexamethasone
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Oct 15, 2026, 7:53 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor

NCT00967343
View directory record Official record
Conditions
Myeloid Leukemia, Lymphoblastic Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndrome, Myeloproliferative Disorders
Interventions
Donor lymphocyte preparation depleted of host functional alloreactive T-cells
Biological
Lead sponsor
Kiadis Pharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 15, 2026, 7:53 PM EDT
Completed Phase 2 Interventional

Total-Body Irradiation and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer and Other Diseases

NCT00317785
View directory record Official record
Conditions
Leukemia, Lymphoma, Myelodysplastic Syndromes
Interventions
cyclophosphamide, cyclosporine, methotrexate, mycophenolate mofetil, sirolimus, tacrolimus, pharmacological study, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, total-body irradiation
Drug · Other · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 7, 2010 · Synced Oct 15, 2026, 7:53 PM EDT
Withdrawn Phase 2 Interventional

High Dose Influenza in Immunosuppressed Subjects

NCT00766285
View directory record Official record
Conditions
Influenza
Interventions
Trivalent inactivated influenza vaccine, Trivalent Baculovirus-expressed Influenza HA vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2015 · Synced Oct 15, 2026, 7:53 PM EDT
Completed Phase 2 Interventional Results available

HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies

NCT00145626
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplasia, Chronic Myeloid Leukemia, Histiocytosis
Interventions
Chemotherapy and antibodies, Miltenyi Biotec CliniMACS, Allogeneic stem cell transplantation
Drug · Device · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 24 Months
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Oct 15, 2026, 7:53 PM EDT
Completed Phase 2 Interventional

Chemotherapy, Filgrastim, and Stem Cell Transplantation With Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer

NCT00004172
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, carboplatin, cyclophosphamide, ifosfamide, thiotepa, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Northwestern University
Other
Eligibility
Up to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 12, 2012 · Synced Oct 15, 2026, 7:53 PM EDT
Completed Phase 1 Interventional

Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation

NCT00185757
View directory record Official record
Conditions
Multiple Myeloma, Blood and Marrow Transplant (BMT)
Interventions
Cytokine Induced Killer Cells
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 15, 2026, 7:53 PM EDT
Recruiting Not applicable Interventional

Massage Impact on Sleep in Pediatric Oncology

NCT06892158
View directory record Official record
Conditions
Cancer, Pediatric Cancer, Chemotherapy Effect, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Pediatric, Hematopoietic Stem Cell Transplantation (HSCT)
Interventions
Massage therapy, Standard of care
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
12 Years to 21 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 15, 2026, 7:53 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies

NCT01419704
View directory record Official record
Conditions
Anemia, Sickle Cell, Complex and Transfusion-dependent Hemoglobinopathies, Thalassemia, Diamond-Blackfan Anemia, Bone Marrow Failure Syndromes, Alpha-Thalassemia, Beta-Thalassemia
Interventions
Enriched Hematopoetic Stem Cell Infusion
Biological
Lead sponsor
Talaris Therapeutics Inc.
Industry
Eligibility
Up to 45 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
3
States / cities
Chicago, Illinois • Louisville, Kentucky • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 3, 2023 · Synced Oct 15, 2026, 7:53 PM EDT
Completed Phase 1 Interventional

Safety, Toxicity and MTD of One Intravenous IV Injection of Donor CTLs Specific for CMV and Adenovirus

NCT00880789
View directory record Official record
Conditions
Cytomegalovirus Infection, Adenovirus Infection
Interventions
CMV/AdV specific T cells
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 90 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Oct 15, 2026, 7:53 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma

NCT01142232
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide plus Melphalan during autologous stem cell transplantation, Lenalidomide maintenance
Drug
Lead sponsor
Attaya Suvannasankha
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Oct 15, 2026, 7:53 PM EDT
Completed Phase 1 Interventional

Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia

NCT03900949
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Cytarabine, Daunorubicin Hydrochloride, Gemtuzumab Ozogamicin, Midostaurin
Procedure · Drug
Lead sponsor
Uma Borate
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Columbus, Ohio • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 15, 2026, 7:53 PM EDT
Completed Phase 2 Interventional Results available

Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders

NCT00553098
View directory record Official record
Conditions
Immunodeficiency Syndrome, Non-Cancer Diagnosis
Interventions
Alemtuzumab, Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Total-Body Irradiation
Biological · Procedure · Drug + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 54 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
6
States / cities
Oakland, California • Cleveland, Ohio • Portland, Oregon + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 15, 2026, 7:53 PM EDT
Recruiting Phase 2 Interventional

Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant

NCT06265584
View directory record Official record
Conditions
Acute Leukemia, Myelodysplastic Syndrome, Myeloproliferative Disorders
Interventions
ATG dosing platform when combined with standard tacrolimus and mini methotrexate
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 75 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Oct 15, 2026, 7:53 PM EDT
Terminated Phase 2 Interventional Results available

A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives

NCT01532635
View directory record Official record
Conditions
Hematologic Malignancy, Leukemia, Acute Lymphoblastic Leukemia, ALL, Acute Myelogenous Leukemia, AML, Chronic Lymphocytic Leukemia, CLL, Lymphoma, Hodgkin's Lymphoma, Non-hodgkin's Lymphoma, Myeloma
Interventions
Total Body Irradiation (TBI), Donor Lymphocyte Infusion (DLI), Cyclophosphamide (CY), Tacrolimus, Mycophenolate Mofetil (MMF), Hematopoietic Stem Cell Transplant (HSCT)
Radiation · Biological · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 15, 2026, 7:53 PM EDT
Terminated Phase 1 Interventional

Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma

NCT05065047
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Belantamab mafodotin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 15, 2026, 7:53 PM EDT
Completed Phase 2 Interventional

Therapy for Children With Advanced Stage High Risk Neuroblastoma

NCT00186849
View directory record Official record
Conditions
Neuroblastoma
Interventions
Topotecan, Cyclophosphamide, Cisplatin, Doxorubicin, Etoposide, Ifosfamide, Carboplatin, Peripheral Blood Stem Cell Transplant
Drug · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 20, 2009 · Synced Oct 15, 2026, 7:53 PM EDT
Completed Not applicable Interventional

Comparing Autologous Peripheral Blood Stem Cell to Bone Marrow Transplantation for Recurrent Non-Hodgkin's Lymphoma

NCT00574626
View directory record Official record
Conditions
Lymphoma
Interventions
PBSCT, Bone Marrow Transplant
Procedure
Lead sponsor
University of Nebraska
Other
Eligibility
16 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2010
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced Oct 15, 2026, 7:53 PM EDT
Completed Phase 2 Interventional Results available

High Dose Intravenous Thiamine for the Prevention of Delirium in Allogeneic Hematopoietic Stem Cell Transplantation

NCT03263442
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplantation, Delirium, Thiamine Deficiency
Interventions
Thiamine, Normal saline
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Oct 15, 2026, 7:53 PM EDT
Terminated Early Phase 1 Interventional

Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB)

NCT00881556
View directory record Official record
Conditions
Epidermolysis Bullosa
Interventions
Palifermin, Fludarabine, Busulfan, Lorazepam, Alemtuzumab, Tacrolimus
Drug
Lead sponsor
Columbia University
Other
Eligibility
Up to 21 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
3
States / cities
Aurora, Colorado • Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Oct 15, 2026, 7:53 PM EDT